[Molecular Tumor Boards in Uro-oncology-prostate Cancer]

Overview

Journal Urologie

Specialty Urology

Date 2024 Aug 6

PMID 39107624

Authors

Frank Kunath

Isabel Heidegger

Matthias Heck

Roman Mayr

Christoph Becker

Steffen Rausch

Affiliations

Soon will be listed here.

Abstract

The rapid development of molecular medicine has opened up new perspectives for the diagnosis and treatment of urological tumors. Urology faces the challenge of effectively treating advanced cancer, especially in view of the genetic diversity of urological tumors. The molecular tumor board offers an innovative approach to identify targeted therapy options based on the individual genetic signatures of tumor cells or tumor microenvironment-based treatment options. In this article, the concept of the molecular tumor board in urology is presented using the example of prostate cancer. We discuss the principles, applications, and future prospects of this promising approach.

References

Horak P, Klink B, Heining C, Groschel S, Hutter B, Frohlich M . Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer. 2017; 141(5):877-886. DOI: 10.1002/ijc.30828. View

Hinderer M, Boerries M, Haller F, Wagner S, Sollfrank S, Acker T . Supporting Molecular Tumor Boards in Molecular-Guided Decision-Making - The Current Status of Five German University Hospitals. Stud Health Technol Inform. 2017; 236:48-54. View

Scheiter A, Hierl F, Luke F, Keil F, Heudobler D, Einhell S . Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre. Br J Cancer. 2022; 128(6):1134-1147. PMC: 10006213. DOI: 10.1038/s41416-022-02120-x. View

Hamamoto R, Koyama T, Kouno N, Yasuda T, Yui S, Sudo K . Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Exp Hematol Oncol. 2022; 11(1):82. PMC: 9620610. DOI: 10.1186/s40164-022-00333-7. View

Russo J, Giri V . Germline testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022; 19(6):331-343. PMC: 9022414. DOI: 10.1038/s41585-022-00580-7. View

de Bono J, Kang J, Hussain M . Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply. N Engl J Med. 2020; 383(9):891. DOI: 10.1056/NEJMc2023199. View

Lang S, Swift S, White H, Misso K, Kleijnen J, Quek R . A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. Int J Oncol. 2019; 55(3):597-616. PMC: 6685596. DOI: 10.3892/ijo.2019.4842. View

Nientiedt C, Tolstov Y, Volckmar A, Endris V, Bonekamp D, Haberkorn U . PARP inhibition in BRCA2-mutated prostate cancer. Ann Oncol. 2016; 28(1):189-191. DOI: 10.1093/annonc/mdw445. View

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

10.

Slootbeek P, Kloots I, Smits M, van Oort I, Gerritsen W, Schalken J . Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. Br J Cancer. 2021; 126(6):907-916. PMC: 8927341. DOI: 10.1038/s41416-021-01663-9. View

11.

Sweeney C, Bracarda S, Sternberg C, Chi K, Olmos D, Sandhu S . Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021; 398(10295):131-142. DOI: 10.1016/S0140-6736(21)00580-8. View

12.

Crabb S, Griffiths G, Marwood E, Dunkley D, Downs N, Martin K . Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). J Clin Oncol. 2020; 39(3):190-201. PMC: 8078455. DOI: 10.1200/JCO.20.01576. View

13.

Eskiler G, Deveci Ozkan A, Haciefendi A, Bilir C . Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro. Transl Oncol. 2021; 15(1):101243. PMC: 8517924. DOI: 10.1016/j.tranon.2021.101243. View

14.

He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S . Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022; 7(1):198. PMC: 9232569. DOI: 10.1038/s41392-022-01042-7. View

15.

Spohn S, Draulans C, Kishan A, Spratt D, Ross A, Maurer T . Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus. Int J Radiat Oncol Biol Phys. 2023; 116(3):503-520. DOI: 10.1016/j.ijrobp.2022.12.038. View

16.

Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-38. PMC: 4201502. DOI: 10.1056/NEJMoa1315815. View

17.

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Nakazawa M . Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015; 1(5):582-91. PMC: 4537351. DOI: 10.1001/jamaoncol.2015.1341. View

18.

Onstenk W, Sieuwerts A, Kraan J, Van M, Nieuweboer A, Mathijssen R . Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol. 2015; 68(6):939-45. DOI: 10.1016/j.eururo.2015.07.007. View

19.

Bernemann C, Schnoeller T, Luedeke M, Steinestel K, Boegemann M, Schrader A . Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol. 2016; 71(1):1-3. DOI: 10.1016/j.eururo.2016.07.021. View

20.

Antonarakis E, Lu C, Luber B, Wang H, Chen Y, Zhu Y . Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol. 2017; 35(19):2149-2156. PMC: 5493048. DOI: 10.1200/JCO.2016.70.1961. View